Tag: AbbVie

AbbVie is a pharmaceutical company that discovers, develops and markets both biopharmaceuticals and small molecule drugs. It originated in 2013 as a spin-off of Abbott Laboratories. On October 19, 2011, Abbott Laboratories announced its plan to separate into two publicly traded companies. The “new” Abbott Laboratories would specialize in diversified products including medical devices, diagnostic equipment and nutrition products, while AbbVie would operate as a research-based pharmaceutical manufacturer.

AbbVie Announced Positive Data from RINVOQ™ Study

abbvie
AbbVie, a research-based global biopharmaceutical company, announced positive top-line data from the SELECT-PsA 2 Phase 3 study. In this study, both doses of RINVOQ™ (upadacitinib; 15 mg and 30 mg, on...

AbbVie Announced Strategic Collaboration with Cystic Fibrosis Foundation

abbvie
AbbVie, a research-based global biopharmaceutical company, and the Cystic Fibrosis Foundation announced a strategic collaboration in which AbbVie will develop a cystic fibrosis transmembrane conductan...

Allergan Shareholders Approved Proposed Acquisition of Allergan by AbbVie

Allergan plc announced that its shareholders have voted to approve the previously announced proposed acquisition of Allergan by AbbVie Inc. As described below, more than 99 percent of the votes cas...

FDA Granted Approval of AbbVie’s MAVYRET®

abbvie
AbbVie, a research-based global biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has granted approval of MAVYRET® (glecaprevir/pibrentasvir) to shorten the once-da...

NICE Recommended AbbVie’s Skyrizi for Plaque Psoriasis

AbbVie’s Skyrizi (risankizumab) has been awarded a positive recommendation from UK drug watchdog NICE, meaning that the IL-23 inhibitor will now be made available to eligible patients across England a...

FDA Approved AbbVie Janus Kinase Inhibitor

AbbVie, a research-based global biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has approved RINVOQ™ (upadacitinib), a 15 mg, once-daily oral Janus kinase (JAK) i...

EU Approved Two New Imbruvica Uses

European regulators have approved AbbVie and Janssen’s Imbruvica (ibrutinib) in two expanded uses that broaden the use of the blood cancer drug. Johnson & Johnson’s pharma unit said the Europea...

R-Pharm Starting Production of Abbvie’s Sevoran Analog

R-pharm
Russian drugmaker R-Pharm is expanding its line of generics of original drugs by starting production of an analog of Sevoran (sevoflurane), which is an anesthetic produced by the US biopharma company ...

AbbVie Acquired Mavupharma Enhancing Early Stage Oncology Pipeline

AbbVie announced that it has acquired Seattle-based Mavupharma, a privately held biopharmaceutical company focused on novel approaches to target the STING (STimulator of INterferon Genes) pathway for ...

AbbVie to Acquire Allergan for $63bn

AbbVie Inc. and Allergan plc announced that the companies have entered into a definitive transaction agreement under which AbbVie will acquire Allergan in a cash and stock transaction for a transactio...

AbbVie Agreed with the pan-Canadian Pharmaceutical Alliance (pCPA) for VENCLEXTA®

abbvie
AbbVie, a global, research and development-driven biopharmaceutical company, announced that Ontario is the first province to reimburse VENCLEXTA® (venetoclax) monotherapy under its Drugs and Devices D...

VENCLEXTA® Received FDA Approval

AbbVie, a research-based global biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has approved VENCLEXTA® (venetoclax) in combination with obinutuzumab (GAZYVA®) fo...

AbbVie and Boehringer Ingelheim Resolve HUMIRA® U.S. Patent Litigation

patents
AbbVie announced that it has resolved U.S. HUMIRA (adalimumab) litigation with Boehringer Ingelheim (BI). Under the terms of the resolution, AbbVie will grant Boehringer Ingelheim a non-exclusive lice...

All HCV Genotypes Drug Approved for Children

The U.S. Food and Drug Administration approved Mavyret (glecaprevir and pibrentasvir) tablets to treat all six genotypes of hepatitis C virus (HCV) in children ages 12 to 17. Mavyret was previously ap...

AbbVie Received EC Approval of Skyrizi

AbbVie has announced that the European Commission (EC) has approved its interleukin-23 (IL-23) inhibitor Skyrizi (risankizumab), for the treatment of moderate to severe plaque psoriasis in adult patie...

AbbVie’s SKYRIZI™ Approved by FDA

AbbVie, a research-based global biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) approved SKYRIZI™ (risankizumab-rzaa), an interleukin-23 (IL-23) inhibitor, for th...